India · Delayed Price · Currency is INR Genpharmasec Statistics
Total Valuation
Genpharmasec has a market cap or net worth of INR 664.46 million. The enterprise value is 723.29 million.
| Market Cap | 664.46M |
| Enterprise Value | 723.29M |
Important Dates
The next estimated earnings date is Wednesday, February 11, 2026.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genpharmasec has 553.72 million shares outstanding. The number of shares has increased by 14.27% in one year.
| Current Share Class | 553.72M |
| Shares Outstanding | 553.72M |
| Shares Change (YoY) | +14.27% |
| Shares Change (QoQ) | -3.21% |
| Owned by Insiders (%) | 45.21% |
| Owned by Institutions (%) | n/a |
| Float | 289.94M |
Valuation Ratios
The trailing PE ratio is 278.25.
| PE Ratio | 278.25 |
| Forward PE | n/a |
| PS Ratio | 0.99 |
| PB Ratio | 1.01 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | 8.69 |
| P/OCF Ratio | 6.78 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 302.88 |
| EV / Sales | 1.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 9.46 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.13 |
| Quick Ratio | 0.60 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 56.94 |
| Debt / FCF | 1.44 |
| Interest Coverage | -1.61 |
Financial Efficiency
Return on equity (ROE) is 0.36% and return on invested capital (ROIC) is -0.26%.
| Return on Equity (ROE) | 0.36% |
| Return on Assets (ROA) | -0.62% |
| Return on Invested Capital (ROIC) | -0.26% |
| Return on Capital Employed (ROCE) | -1.32% |
| Weighted Average Cost of Capital (WACC) | -0.15% |
| Revenue Per Employee | 67.17M |
| Profits Per Employee | 238,800 |
| Employee Count | 10 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 3.97 |
Taxes
In the past 12 months, Genpharmasec has paid 10.78 million in taxes.
| Income Tax | 10.78M |
| Effective Tax Rate | 81.86% |
Stock Price Statistics
The stock price has decreased by -57.91% in the last 52 weeks. The beta is -0.84, so Genpharmasec's price volatility has been lower than the market average.
| Beta (5Y) | -0.84 |
| 52-Week Price Change | -57.91% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 1.83 |
| Relative Strength Index (RSI) | 38.72 |
| Average Volume (20 Days) | 616,383 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genpharmasec had revenue of INR 671.74 million and earned 2.39 million in profits. Earnings per share was 0.00.
| Revenue | 671.74M |
| Gross Profit | 67.58M |
| Operating Income | -9.81M |
| Pretax Income | 13.17M |
| Net Income | 2.39M |
| EBITDA | -2.73M |
| EBIT | -9.81M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 50.38 million in cash and 110.13 million in debt, with a net cash position of -59.74 million or -0.11 per share.
| Cash & Cash Equivalents | 50.38M |
| Total Debt | 110.13M |
| Net Cash | -59.74M |
| Net Cash Per Share | -0.11 |
| Equity (Book Value) | 655.87M |
| Book Value Per Share | 1.12 |
| Working Capital | 64.93M |
Cash Flow
In the last 12 months, operating cash flow was 97.96 million and capital expenditures -21.46 million, giving a free cash flow of 76.50 million.
| Operating Cash Flow | 97.96M |
| Capital Expenditures | -21.46M |
| Free Cash Flow | 76.50M |
| FCF Per Share | 0.14 |
Margins
Gross margin is 10.06%, with operating and profit margins of -1.46% and 0.36%.
| Gross Margin | 10.06% |
| Operating Margin | -1.46% |
| Pretax Margin | 1.96% |
| Profit Margin | 0.36% |
| EBITDA Margin | -0.41% |
| EBIT Margin | -1.46% |
| FCF Margin | 11.39% |
Dividends & Yields
Genpharmasec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.27% |
| Shareholder Yield | -14.27% |
| Earnings Yield | 0.36% |
| FCF Yield | 11.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 11, 2019. It was a forward split with a ratio of 10.
| Last Split Date | Apr 11, 2019 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |